![Thomas S. Clement](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Thomas S. Clement
Keine laufenden Positionen mehr
Profil
Thomas S.
Clement worked as a Quality Manager at Biotech Research Labs, Inc. from 1984 to 1988.
He then worked as a Manager-Regulatory Affairs at Amersham Corp.
in 1989.
From 1989 to 2002, he worked as a Director-Regulatory Affairs at Organon Teknika Corp.
LLC.
Later, he worked as a Vice President-Quality & Regulatory Affairs at Roche Molecular Systems, Inc. from 2002 to 2008.
In 2009 to 2011, he worked as a VP-Global Regulatory & Clinical Affairs at QIAGEN NV.
He also worked as a Vice President-Regulatory & Quality Affairs at LipoScience, Inc. Mr. Clement completed his undergraduate degree from the University of Maryland.
Ehemalige bekannte Positionen von Thomas S. Clement
| Unternehmen | Position | Ende |
|---|---|---|
| QIAGEN N.V. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2011 |
Roche Molecular Systems, Inc.
 Roche Molecular Systems, Inc. Medical/Nursing ServicesHealth Services Develops & produces molecular-based diagnostic tests & automated testing platforms | General Counsel | 01.01.2008 |
Organon Teknika Corp. LLC
 Organon Teknika Corp. LLC Financial ConglomeratesFinance Led by management of PerImmune | General Counsel | 01.01.2002 |
Amersham Corp.
 Amersham Corp. Investment ManagersFinance Amersham Corp. focuses on the acquisition and ownership of mid-sized manufactures of precision engineered components and assemblies with particular interest in aerospace, automotive and medical device manufacturers and suppliers. The firm invests in small to medium sized companies with annual sales of $10 million to $200 million | General Counsel | 01.01.1989 |
Biotech Research Labs, Inc.
 Biotech Research Labs, Inc. MiscellaneousMiscellaneous Operates as a non-classified establishment | Corporate Officer/Principal | 01.01.1988 |
Ausbildung von Thomas S. Clement
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
19
Beziehungen ersten Grades
7
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 7 |
|---|---|
QIAGEN NV
 QIAGEN NV Medical SpecialtiesHealth Technology Manufactures and distributes sample and assay technology products for pre-analytical sample preparations | Health Technology |
LipoScience, Inc.
 LipoScience, Inc. Medical SpecialtiesHealth Technology Operates as an in vitro diagnostic company for cardiovascular and metabolic diseases using technology platform based on nuclear magnetic resonance | Health Technology |
Amersham Corp.
Amersham Corp. Investment ManagersFinance Amersham Corp. focuses on the acquisition and ownership of mid-sized manufactures of precision engineered components and assemblies with particular interest in aerospace, automotive and medical device manufacturers and suppliers. The firm invests in small to medium sized companies with annual sales of $10 million to $200 million | Finance |
Organon Teknika Corp. LLC
Organon Teknika Corp. LLC Financial ConglomeratesFinance Led by management of PerImmune | Finance |
University of Maryland
 University of Maryland Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Roche Molecular Systems, Inc.
Roche Molecular Systems, Inc. Medical/Nursing ServicesHealth Services Develops & produces molecular-based diagnostic tests & automated testing platforms | Health Services |
Biotech Research Labs, Inc.
Biotech Research Labs, Inc. MiscellaneousMiscellaneous Operates as a non-classified establishment | Miscellaneous |
